Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2021-08-06 00:00:00 ET · period of report 2021-08-04 · accession 0001209191-21-050228 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-08-06 | 2021-08-04 | NTLA | Sepp-Lorenzino Laura | EVP, CSO | S - Sale+OE | $138.24 | -26.0K | 20.1K | -56% | -$3.59M |
| D | 2021-08-06 | 2021-08-04 | NTLA | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | $13.40 | +26.0K | 28.4K | +1,087% | +$348.4K |
| D | 2021-08-06 | 2021-08-04 | NTLA | Sepp-Lorenzino Laura | EVP, CSO | M - OptEx | $0.00 | -26.0K | 109.0K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-04 | S | D | 1,471 | $135.47 | 26,920 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.18 to $135.885, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| 2 | Common | Common Stock | 2021-08-04 | S | D | 6,344 | $137.72 | 13,762 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.255 to $138.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| 3 | Common | Common Stock | 2021-08-04 | M | A | 26,000 | $13.40 | 28,391 | D | — | — | |
| 4 | Common | Common Stock | 2021-08-04 | S | D | 126 | $141.63 | 2,391 | D | — | — | (F8) Includes shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan as follows: 760 shares on December 31, 2019; 847 shares on June 30, 2020; 561 shares on December 31, 2020 and 223 shares on June 30, 2021. |
| 5 | Common | Common Stock | 2021-08-04 | S | D | 4,054 | $140.73 | 2,517 | D | — | — | (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.395 to $141.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| 6 | Common | Common Stock | 2021-08-04 | S | D | 2,772 | $139.85 | 6,571 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.395 to $140.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| 7 | Common | Common Stock | 2021-08-04 | S | D | 4,419 | $138.78 | 9,343 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.31 to $139.305, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| 8 | Common | Common Stock | 2021-08-04 | S | D | 6,814 | $136.79 | 20,106 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.25 to $137.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 4, 2021 at each separate price. |
| 9 | Derivative | Stock Option (right to buy) | 2021-08-04 | M | D | 26,000 | $0.00 | 109,000 | D | $13.40 · — to 2030-03-01 | 26,000 Common Stock | (F9) The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 53,437 shares as of August 4, 2021. |